Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.53 |
| ▸ | PRKCB | P05771 | 6/20 | 0.53 |
| ▸ | PRKCA | P17252 | 3/20 | 0.47 |
| ▸ | PRKCG | P05129 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 10/20 | 0.47 |
| ▸ | CNR1 | P21554 | 9/20 | 0.47 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20697023 | 0.87 | CNR2 (0.53) | GSK3BPRKCBCNR2CNR1 | |
| SCHEMBL20688049 | 0.81 | GSK3B (0.56) | GSK3BPRKCBPRKCAPRKCGCNR2 | |
| SCHEMBL18993230 | 0.81 | DYRK1A (0.49) | GSK3BPRKCBCNR2CNR1 | |
| SCHEMBL21227337 | 0.78 | GSK3B (0.53) | GSK3BPRKCBPRKCAPRKCGCNR2 | |
| SCHEMBL21245970 | 0.77 | HTR6 (0.42) | GSK3BCNR2CNR1 | |
| SCHEMBL21227429 | 0.77 | HTR6 (0.49) | CNR2CNR1 | |
| SCHEMBL21600843 | 0.77 | CNR2 (0.52) | GSK3BPRKCBPRKCACNR2CNR1 | |
| SCHEMBL21227426 | 0.76 | CNR2 (0.50) | GSK3BCNR2CNR1 | |
| SCHEMBL21227335 | 0.76 | REN (0.45) | GSK3BPRKCBPRKCA | |
| SCHEMBL820570 | 0.76 | DYRK1A (0.47) | GSK3BIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046698-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-22 | — | — | US | disclosed |
| US-20190241577-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046698-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | GSK3B 122/4885PRKCB 460/4885PRKCA 705/4885 |
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | GSK3B 122/4885PRKCB 460/4885PRKCA 705/4885 |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | GSK3B 122/4885PRKCB 460/4885PRKCA 705/4885 |
| US-20190241577-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | GSK3B 122/4885PRKCB 460/4885PRKCA 705/4885 |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | GSK3B 122/4885PRKCB 460/4885PRKCA 705/4885 |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | GSK3B 122/4885PRKCB 460/4885PRKCA 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.